Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study
Authors:
Open Access
- 5 May 2011
- journal article
- research article
- Published by Hindawi Limited in Advances in Urology
- Vol. 2011, 1-5
Abstract
Objective. To assess the efficacy and the effect on Qol of solifenacin for the treatment of OAB in MS patients.Patients and Methods. Thirty MS patients suffering from OAB were treated with solifenacin 5/10 mg for 8 weeks. The first 4 weeks patients received solifenacin 5 mg. At week 4 patients could request a dose increase to 10 mg. The efficacy was evaluated at 8 weeks.Results. After 4 weeks of treatment, 28 patients reported acceptable or no side effects. 17 continued the study with the 10 mg dosage, and 11 stayed on 5 mg solifenacin. Two patients withdrew from the study due to side effects. Solifenacin 5/10 mg for 8 weeks resulted in a significant decrease in number of micturitions and number of pads used per day compared to baseline. Also the severity of urgency prior to voiding decreased significantly, and an increase was seen in the volume per void. Twenty out of 30 patients chose to continue solifenacin therapy after termination of the study. The majority of patients reported global QoL improvement.Conclusions. Solifenacin is effective in the treatment of MS patients with OAB symptoms. This is the first study with solifenacin in a specific neurogenic patient group with a neurogenic disease-specific QoL outcome measure (MS-QoL 54).Keywords
This publication has 17 references indexed in Scilit:
- Solifenacin significantly improves all symptoms of overactive bladder syndromeInternational Journal Of Clinical Practice, 2006
- Quality of life in women with multiple sclerosis and overactive bladder syndromeInternational Urogynecology Journal, 2006
- Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladderBJU International, 2004
- Can Higher Doses of Oxybutynin Improve Efficacy in Neurogenic Bladder?Journal of Urology, 2004
- Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo‐ and tolterodine‐controlled phase 2 dose‐finding studyBJU International, 2003
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- Tolterodine: a new antimuscarinic agent for the treatment of the overactive bladderExpert Opinion on Investigational Drugs, 1999
- Relationship Between Lower Urinary Tract Abnormalities and Disease-Related Parameters in Multiple SclerosisJournal of Urology, 1995
- A health-related quality of life measure for multiple sclerosisQuality of Life Research, 1995
- Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis.Journal of Neurology, Neurosurgery & Psychiatry, 1993